در هنگام جستجو کلمه در قسمت عنوان میتوانید کلمات مورد جستجو را با کاراکتر (-) جدا کنید.
کاربرد نوع شرط:
- جایگاه : پژوهشی
- مجله: Journal of Dental Materials and Techniques
- نوع مقاله: Journal Article
- کلمات کلیدی: Composite,Infection Control,Protective sleeve,Output intensity of LED light cure
- چکیده:
- چکیده انگلیسی: Aim: The purpose of this study was to compare the difference in the output intensity of Light Emitting Diode (LED) light cure (LC) devices with and without a protective sleeve and its clinical significance.
Materials and Methods: The output intensity of 152 LC units in dental offices across the state of Odisha were examined. The collection of related information included an average number of exposures per day and the charging status. LED Radiometer (SDI Ltd, VIC, AUS) was used for measuring output intensity.
Results: Out of all the 152 LC devices examined, 137 were found to emit light intensity above minimum baseline values when used with a protective sleeve. The decrease in output intensity, when used with a protective sleeve was statistically significant (p<0.05). 78 LC devices with direct current supply, maintained better intensity than battery operated ones. 74 battery operated LC devices showed statistically significant differences (p<0.05) in intensity output based on the number of exposures/day. Devices that were being charged daily maintained significantly (p<0.05) better intensity output than those being charged once or twice a week.
Conclusion: LED Light cure devices can be safely used along with a protective sleeve to improve cross infection control without affecting its output intensity. Battery operated LED devices must be charged at least 3 times/ week to prevent a significant decrease in output intensity- انتشار مقاله: 25-01-1395
- نویسندگان: Amit Jena,Satyajit Mohapatra,Govind Shashirekha
- مشاهده
- جایگاه : پژوهشی
- مجله: Asian Pacific Journal of Cancer Prevention
- نوع مقاله: Journal Article
- کلمات کلیدی: Trastuzumab,HER2 monoclonal antibody,BRAF,KRAS,PIK3CA
- چکیده:
- چکیده انگلیسی:
Studies show that approximately 20% of all breast cancer patients have a breast tumor that tests positive for Human Epidermal Growth Factor Receptor 2, otherwise known as the HER2 gene. As such, treatments for breast cancer usually include drugs that target HER2. The drug Trastuzumab is a recombinant antibody that has been approved by the FDA for the treatment of these HER2 positive breast cancers. However, researchers have found that mutations in associated genes, PIK3CA and KRAS, can cause the tumor to become resistant to Trastuzumab. The purpose of this article is to evaluate the sensitivity of the cancer cell lines to the drug Trastuzumab and investigate how this sensitivity is compromised by the PIK3CA, KRAS and BRAF gene mutations. Trastuzumab responsiveness was evaluated in breast cancer cell lines by treating the lines with an optimal concentration of the drug followed by a proliferation assay of the cell lines in the presence of monoclonal antibodies. We determined the optimum concentration of Trastuzumab to be 7 μg/well. The BRAF and KRAS mutated cell line, MDA-MB-231, showed the least sensitivity after being treated with trastuzumab when compared to the sensitivity of the PIK3CA mutated cell lines, MCF-7 and MDA-MB-361, and the KRAS/ BRAF/ PIK3CA cell line, MDA-MB-453. Clinical observations show that mutations in BRAF and KRAS genes in breast cancer cells do lower the responsiveness of Trastuzumab drug treatments.- انتشار مقاله: 22-02-1396
- نویسندگان: Satyajit Patra,Vanesa Young,Leslie Llewellyn,Jitendra Senapati,Jesil Mathew
- مشاهده